Unknown

Dataset Information

0

Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease.


ABSTRACT: Lipopolysaccharide (LPS) inhalation causes increased airway and systemic inflammation. We investigated LPS inhalation in patients with chronic obstructive pulmonary disease (COPD) as a model of bacterial exacerbations. We studied safety, changes in sputum and systemic biomarkers. We have also investigated interleukin (IL)-17 concentrations in this model.Twelve COPD patients inhaled 5 ?g LPS. Safety was monitored over 24 h. Sputum was induced at baseline, 6 and 24 h for cells and IL-8, IL-17, neutrophil elastase, monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1? (MIP-1?) in supernatants. Serum was collected at baseline, 4, 8 and 24 h for IL-6, C-reactive protein (CRP) and Clara cell protein (CC-16) concentrations. Peripheral blood mononuclear cells (PBMCs) were isolated at baseline and 4 h for systemic IL-17 analysis.LPS 5 ?g was well tolerated. The greatest FEV1 change was 11.7% (mean) at 1 h (95% CI 5.1-18.2%). There was a large range in maximal fall (2.5-37.7%). Total sputum cell count and neutrophil count significantly increased 6 and 24 h post-LPS. There was no change in sputum supernatant mediators. IL-6, CRP and CC-16 increased post-inhalation, with different temporal patterns. CD4+ and CD8+ cell associated IL-17 significantly increased at 4 h.Inhaled LPS in COPD patients safely causes increased airway and systemic inflammation. This may be a model for studying COPD exacerbations.

SUBMITTER: Gupta V 

PROVIDER: S-EPMC4415713 | biostudies-other | 2015 May

REPOSITORIES: biostudies-other

altmetric image

Publications

Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease.

Gupta Vandana V   Banyard Antonia A   Mullan Aoibheann A   Sriskantharajah Srividya S   Southworth Thomas T   Singh Dave D  

British journal of clinical pharmacology 20150501 5


<h4>Aims</h4>Lipopolysaccharide (LPS) inhalation causes increased airway and systemic inflammation. We investigated LPS inhalation in patients with chronic obstructive pulmonary disease (COPD) as a model of bacterial exacerbations. We studied safety, changes in sputum and systemic biomarkers. We have also investigated interleukin (IL)-17 concentrations in this model.<h4>Methods</h4>Twelve COPD patients inhaled 5 μg LPS. Safety was monitored over 24 h. Sputum was induced at baseline, 6 and 24 h f  ...[more]

Similar Datasets

| S-EPMC6626346 | biostudies-literature
| S-EPMC5759273 | biostudies-literature
| S-EPMC6003532 | biostudies-other
2003-07-16 | GSE475 | GEO
| S-EPMC8689000 | biostudies-literature
| S-EPMC5440622 | biostudies-literature
| S-EPMC10607211 | biostudies-literature
| S-EPMC7605197 | biostudies-literature
| S-EPMC4776680 | biostudies-literature
| S-EPMC8966042 | biostudies-literature